Cleveland Clinic Study Shows Less Weight Regain After Stopping Ozempic and Wegovy Than Expected

About this episode

A study from Cleveland Clinic reveals that patients regain less weight after stopping Ozempic and Wegovy than previously thought.

Recent research from Cleveland Clinic is challenging what many people thought they knew about stopping weight loss medications like Ozempic and Wegovy. A new study published in the journal Diabetes, Obesity and Metabolism analyzed nearly eight thousand patients who used semaglutide or tirzepatide for three to twelve months before discontinuing treatment. The findings offer surprising hope compared to earlier clinical trials that suggested dramatic weight regain after stopping these drugs. In the real world, patients who stopped taking these medications regained far less weight than researchers expected. Among those treated specifically for obesity, the average weight loss before stopping was eight point four percent. One year later, they had regained just half a percent on average. The key difference between this study and previous clinical trials comes down to what happens after patients stop. In real world settings, patients have more options. According to lead researcher Dr. Hamlet Gasoyan from Cleveland Clinic, many patients who stop taking semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which explains why they regain less weight…

Topics covered

• weight loss medications
• obesity treatment
• clinical research
• weight regain
• real world outcomes

Keywords

• Cleveland Clinic
• Ozempic
• Wegovy
• weight regain
• semaglutide
• tirzepatide
• obesity
• clinical trials

Mentioned in this episode

Organizations: Cleveland Clinic

Products: Ozempic, Wegovy, semaglutide, tirzepatide

Books & works: Diabetes, Obesity and Metabolism

More episodes of Oprah's Weight Loss Dilemma: The Ozempic

• Unable to Generate Ozempic Headline Without Relevant Search Results Data · May 2, 2026 · 1 min
• ChatGPT Under Investigation for Florida State University Shooting Investigation Reveals AI Safety Concerns · April 25, 2026 · 3 min
• AI Bias Tools and Security Risks Emerge as Developers Face New Challenges in Text to Image and Coding Systems · April 22, 2026 · 2 min
• Ozempic Weight Loss Updates April 2026: Doctors Emphasize Lifestyle Changes Alongside Medication · April 18, 2026 · 2 min
• Ozempic Shortage Crisis 2026 Demand Surges as Novo Nordisk Struggles with Supply Chain Delays · April 11, 2026 · 3 min
• Florida Law Enforcement Warns Against AI Deepfake Crime Videos as Pranks Waste Critical Resources · April 8, 2026 · 3 min